16 October 2024 | 11:15 - 12:45
With the advent of Google’s Alphafold2 (3D models) and OpenAI’s ChatGPT4 (Large language models), researchers anticipate game changes in drug development. Alphafold2 would allow structure based drug design in every disease area and ChatGPT could help in diagnoses and personalize medicine. Furthermore AI is used to help set up large international phase 3 trials. However, training the models well depends on the quality of the data used and access to positive as well as negative data, disease as well as healthy data. What is the current status?
Chairs: Ed Moret (UIPS), Gerard van Westen (LACDR)
Speakers: Sanne Abeln (Utrecht University), Chris Klijn (Genmab)
Contact | Connect | ||||
Veerstraat 27 1211 HJ Hilversum Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 |
| Register now | |||
© Copyright 2023 by Hyphen Projects | All rights reserved |